Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $10.71, moving -0.19% from the previous trading session. This move lagged the S&P 500's daily gain of 0.64%. Elsewhere, the Dow gained 1.39%, while the tech-heavy Nasdaq added 0.52%.
Investors will be hoping for strength from ACB as it approaches its next earnings release. Meanwhile, our latest consensus estimate is calling for revenue of $54.37 million, down 36.32% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for ACB. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.38% lower. ACB is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 194, which puts it in the bottom 24% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Click to get this free report
Aurora Cannabis Inc. (ACB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.